TL;DR
Current data support the incorporation of tumor genomic analysis into routine clinical decision-making as an important step toward precision-based care in endometrial cancer, and suggest that molecular profiling may better identify patients who would benefit from treatment intensification or de-escalation compared with conventional risk assessment alone.
Background Stage II colon cancer is clinically heterogeneous. Current clinicopathologic risk factors cannot accurately identify patients with residual disease after curative resection. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD), defined as micr...
Molecular classification has emerged as a promising tool to improve patient selection and prognostic stratification in fertility sparing treatment (FST) for endometrial cancer (EC). Although FST is currently considered a valid option for carefully selected patients with early stage, low grade endometrioid EC, recurrenc...
The postoperative management of resectable solid tumors depends on clinicopathological risk stratification. However, these static criteria often fail to identify occult minimal residual disease (MRD), resulting in suboptimal adjuvant treatment characterized by either overtreatment or undertreatment. Circulating tumor D...
Abstract Circulating tumor DNA (ctDNA) is an increasingly important biomarker for molecular residual disease (MRD) after curative-intent treatment of colorectal cancer (CRC), but its prognostic value must be distinguished from proven clinical utility. This structured narrative review synthesizes evidence from PubMed/ME...
Treatment delivered before surgery in colorectal cancer now encompasses several clinically distinct strategies rather than one uniform pathway. These include selective neoadjuvant chemotherapy for radiologically high-risk colon cancer, total neoadjuvant therapy (TNT) and response-adapted organ preservation in rectal ca...
PURPOSE OF REVIEW Despite maximal neoadjuvant chemoimmunotherapy, nearly 40% of early-stage triple-negative breast cancer (TNBC) patients fail to achieve pathological complete response, underscoring an urgent need for biomarkers capable of guiding treatment modulation. This review summarizes recent advances in tumor-in...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
